Analyse Bristol-Myers Squibb stock

Confirmed: The consensus price target of 55.33 EUR is only around 8.9% above the current price of 50.81 EUR and is therefore clearly within the required +/-25% plausibility range.
Fundamental: With a P/E ratio of 10.41Bristol-Myers Squibb appears moderately valued in the pharmaceutical sector; the valuation already reflects patent expiration, pipeline and growth risks. Compared to large-cap pharmaceutical peers, a target in the mid-single-digit to low double-digit upside range seems plausible, but not a strong re-rating.
History/Technology: The price is trading near the 52-week high of EUR 54.96 and well above the 52-wee...